Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab
I Bruns, F Fox, P Reinecke, G Kobbe, R Kronenwett… - Leukemia, 2005 - nature.com
I Bruns, F Fox, P Reinecke, G Kobbe, R Kronenwett, G Jung, R Haas
Leukemia, 2005•nature.comPatients with angioimmunoblastic T-cell lymphoma (AITL) have a poor prognosis following
conventional cytotoxic chemotherapy. With median remission rates of up to 50% achieved
by combination chemotherapy, the probability of relapse is great, resulting in a median
survival time of 36 months, with a range between 2 and 108 months. 1 The histomorphology
of AITL is characterized by a prominent vascular component, 2 which is crucial for tumor
growth, invasion and metastasis. 3 In a few patients with AITL not responding to …
conventional cytotoxic chemotherapy. With median remission rates of up to 50% achieved
by combination chemotherapy, the probability of relapse is great, resulting in a median
survival time of 36 months, with a range between 2 and 108 months. 1 The histomorphology
of AITL is characterized by a prominent vascular component, 2 which is crucial for tumor
growth, invasion and metastasis. 3 In a few patients with AITL not responding to …
Patients with angioimmunoblastic T-cell lymphoma (AITL) have a poor prognosis following conventional cytotoxic chemotherapy. With median remission rates of up to 50% achieved by combination chemotherapy, the probability of relapse is great, resulting in a median survival time of 36 months, with a range between 2 and 108 months. 1
The histomorphology of AITL is characterized by a prominent vascular component, 2 which is crucial for tumor growth, invasion and metastasis. 3 In a few patients with AITL not responding to conventional cytotoxic chemotherapy compounds with an antiangiogenetic effect, such as thalidomide, have been used and found to be effective to some extend. 4 We report here on a patient achieving complete remission as a result of single-agent treatment with the chimeric anti-VEGF monoclonal antibody bevacizumab (Avastin®).
nature.com